BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 11.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,928,094 shares of the medical technology company's stock after buying an additional 297,850 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 2.07% of Alphatec worth $16,280,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Jennison Associates LLC purchased a new position in shares of Alphatec in the third quarter valued at approximately $686,000. Wrapmanager Inc. raised its stake in Alphatec by 9.5% in the 3rd quarter. Wrapmanager Inc. now owns 38,399 shares of the medical technology company's stock valued at $213,000 after purchasing an additional 3,325 shares during the last quarter. Royce & Associates LP lifted its holdings in Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after purchasing an additional 165,954 shares in the last quarter. Zions Bancorporation N.A. boosted its stake in Alphatec by 108.2% during the 3rd quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company's stock worth $963,000 after purchasing an additional 89,992 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Alphatec during the third quarter worth $431,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Trading Down 1.5 %

NASDAQ:ATEC traded down $0.15 during trading hours on Friday, reaching $10.06. 1,122,129 shares of the stock were exchanged, compared to its average volume of 3,035,940. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34. The business has a 50-day moving average of $6.71 and a two-hundred day moving average of $8.22. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.86 and a beta of 1.31. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Analyst Upgrades and Downgrades

ATEC has been the topic of several research reports. Wells Fargo & Company decreased their price target on shares of Alphatec from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus dropped their price target on Alphatec from $19.00 to $16.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Morgan Stanley downgraded Alphatec from an "overweight" rating to an "equal weight" rating in a research report on Thursday, August 1st. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Thursday, October 31st. Finally, Lake Street Capital cut their target price on Alphatec from $32.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.11.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.